Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Yum China Holdings Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B), while Yum China Holdings Inc trades at $43.91 (market cap $15.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.1× Yum China Holdings Inc's market cap, and Yum China Holdings Inc pays a 2.64% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | YUMC | |
|---|---|---|
Market Cap | $121.95B | $15.09B |
Sector | Health | Consumer Cyclical |
52-Week High | $529.59 | $57.95 |
52-Week Low | $366.54 | $40.18 |
Enterprise Value | $116.69B | $15.98B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
YUMC trades at $42.77, down 2.51% today, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company shows consistent revenue growth, reaching $11.80B in 2025, and has beaten earnings estimates in three consecutive quarters. Recent strategic moves include the acquisition of Pizza Hut China, enhancing local control and cost synergies. Analyst sentiment remains strongly positive with 14 buy ratings and no sell recommendations.
The outlook for YUMC is favorable due to solid fundamentals and strategic initiatives, though risks include macroeconomic headwinds in China and competitive pressures. Valuation metrics like a P/E of 16.83 and EV/EBITDA of 8.76 suggest reasonable pricing relative to earnings, supporting potential upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
